



Brooks Automation Conference Call

FY'20 Second Quarter Financial Results

April 30, 2020

Safe Harbor Statement



"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. Further discussions of risk factors are available in the Company's most recent SEC filings including form 10-K for the fiscal year ended September 30, 2019. The Company assumes no obligation to update the information in this presentation.

Regulation G

This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Brooks business and its operational performance. These measures should always be considered in conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant GAAP amount are provided in either an attachment to our second quarter financial results press release issued on April 30, 2020 or as an attachment to call slides used to accompany prepared comments made during our financial results conference call of the same date. Both documents are available on our website at www.brooks.com.

Brooks Q2 FY 2020 Overview



- ✓ Diversified revenue streams fuel double-digit revenue growth of 11%
 - ➤ Life Sciences 11% growth YtY, with organic growth of 11%
 - ➤ Semiconductor 11% growth YtY and 5% sequential expansion
- ✓ Business model with leverage delivers margin expansion and EPS growth
 - ➤ Non-GAAP EPS increased 48% YtY: \$0.25 per share, + \$0.08
 - Sample Management gross margins up 570 basis points YtY
- ✓ Strong liquidity with \$198 million net cash
 - ➤ Adjusted operating cash flow of \$26 million











Brooks Automation Operating Performance Quarter ended March 31, 2020

Brooks

	GAA	P	n	non-GAAP			
	Q2'20	QtQ	Q2'20	QtQ	YtY		
Revenue	220	5%	220	5%	11%		
Gross profit	90	6%	93	6%	12%		
%	41.0%	0.6 pts.	42.2%	0.6 pts.	0.2 pts.		
R&D	15	6%	15	6%	9%		
SG&A	60	1%	52	1%	14%		
Restructuring	1_	0%		n/a	n/a		
Operating Income	14.6	37%	26	17%	10%		
%	6.6%	1.6 pts.	11.7%	1.2 pts.	(0.1) pts.		
Interest Income (Expense)	(0.6)	(\$1)	(0.6)	(\$1)	\$7		
Other Income (Expense)	(1.4)	(\$1)	(1.4)	(\$1)	(\$1)		
Tax Benefit (Expense)	(3.4)	(\$6)	(5.4)	(\$0)	(\$3)		
Net Income - continuing ops	9.2	(\$4)	18.5	11%	51%		
%	4.2%	(2.1) pts.	8.4%	0.5 pts.	2.2 pts.		
Diluted EPS - continuing ops	\$ 0.12	\$ (0.05)	\$ 0.25	\$ 0.02	\$ 0.08		
Adjusted EBITDA			34.8	9%	6%		

- High demand, strong supply chain, and adaptive workforce
- Operating leverage of two strong businesses drives margin expansion and EPS growth

Brooks Life Sciences Performance



\$ millions non-GAAP

	Q2'20	QtQ	YtY
Revenue	95	4%	11%
Organic			11%
Gross profit	44	8%	20%
%	45.8%	1.5 pts.	3.3 pts.
Operating expenses	36	3%	13%
Operating income	8	36%	62%
%	<i>8.5%</i>	2.0 pts.	2.6 pts.

- Organic revenue growth of 11%
 - GENEWIZ drove 25% organic growth on strong NGS and Synthesis growth
 - Sample Management drove 3% organic growth
- Operating Margin expansion driven by continued gross margin improvement
 - Sample Management up 570 basis points YtY
 - Favorable mix from higher GENEWIZ growth

Brooks Semiconductor Solutions Performance



\$ millions Continuing Operations - non-GAAP

	Q2'20	QtQ	YtY
Revenue	125	5%	11%
Organic			11%
Gross profit	49	5%	5%
%	39.5%	(0.1) pts.	(2.0) pts.
Operating expenses	33	2%	17%
Operating income	17	11%	(12%)
%	<i>13.4%</i>	0.7 pts.	(3.4) pts.

- Second consecutive quarter of record level revenue from Contamination Control Solutions
- Operating margin expanded sequentially and down YtY
 - Gross margins stable sequentially but down year over year driven by mix
 - Gross margin improvement in robots, CCS, and services
 - Operating expense increased on R&D investment and Corporate expense

Summary Cash Flow

Brooks

	Q2'20	YTD'20
Net income	9	22
Deferred income tax benefit	(1)	(9)
Depreciation & amortization	17	33
Stock compensation	4	9
Change in working capital	(3)	(4)
Other operating items	0	1
Adjusted operating cash flow	26	51
Income taxes payable - Cryo Sale	(92)	(92)
Cash flow from operations	(66)	(40)
Capital expenditures	(12)	(21)
Free Cash Flow	(77)	(61)
Divestitures (Acquisitions) Net	(16)	(16)
Payments of debt	-	(0)
Dividends	(7)	(15)
Other	(4)	(1)
Net change in cash and marketable sec.	(105)	(94)

- \$26 million of adjusted cash flow from operations
 - ➤ Reported cash flow from operations includes \$92 million of tax payments related to the 2019 sale of the Semiconductor Cryo business
- Used \$12 million of cash for growth CAPEX and \$16 million for RURO acquisition

Summary Balance Sheet

Quarter Ended March 31, 2020



	Dec 31 2019	Mar 31 2020	QtQ
Cash, restricted cash, and marketable securities	353	249	(105)
Accounts receivable, net	165	179	14
Inventories	105	108	3
Other current assets	43	40	(3)
Accounts payable	(65)	(64)	1
Deferred revenue	(29)	(29)	(0)
Short-term debt	(1)	(1)	(0)
Other current liabilities	(188)	(103)	85
Net working capital	30	130	99
Property, plant and equipment	105	109	3
Goodwill and intangible assets	733	735	2
Long-term debt	(50)	(50)	(0)
Net long-term deferred tax assets (liabilities)	(8)	(7)	1
Other net long-term assets (liabilities)	(5)	(3)	2
Net assets	1,159	1,161	2

- \$249 million of cash and marketable securities
- \$198 million of net cash available for operations and investments

Summary and Guidance




	Q2'20	Guidance Q3'20
Revenue	\$220	\$200 - \$215
Adjusted EBITDA	\$35	\$26 - \$34
Non-GAAP diluted EPS	\$0.25	\$0.16 - \$0.24
GAAP diluted EPS - Total Brooks	\$0.12	\$0.04 - \$0.12

√ Fundamentals of the business remain strong for the long term

- Leadership positions in both markets
- Strong liquidity provides strategic flexibility

✓ Our momentum in the market remains strong with near-term caveats

- Semi Capex environment depends on decisions of the concentrated end-users and continuity of the industry supply chain
- ➤ Life Sciences' pharma, biotech, and clinical markets are actively feeding our momentum, while academic research has not returned
- Maintaining investments now to keep team in place, accelerate development, and to extend our leadership during these turbulent times





GAAP to Non-GAAP Bridges

Reconciliation of GAAP to Non-GAAP – Q2'20 Continuing Operations



	GAAP Results Q2 FY20	Merger and Acquisition Costs	Amortization Expense	Restructuring Charges	Tax Effect on Adjustments	Other Tax Items	Non-GAAP Results Q2 FY20
Revenue	220.2	_	_	-	_	_	220.2
Gross profit	90.3	-	2,7	-	-	-	93.0
Gross profit margin	41.0%						42.2%
Operating Expenses	(75.1)	0.3	7.6	-	-	-	(67.2)
Restructuring charges	(0.6)	-	-	0.6	-	-	`-
Operating profit	14.6	0.3	10.4	0.6	-	-	25.8
Operating profit margin	6.6%						11.7%
Interest expense, net	(0.6)	-	-	-	-	-	(0.6)
Other income (expense), net	(1.4)	-	-	-	-	-	(1.4)
Income tax benefit (provision)	(3.4)	-	-	-	(3.0)	1.0	(5.4)
Net Income	9.2	0.3	10.4	0.6	(3.0)	1.0	18.5
Diluted EPS	0.12	0.00	0.14	0.01	(0.04)	0.01	0.25

GAAP to Non-GAAP Reconciliation Q2'20 Segments – Continuing Operations

Brooks

	GAAP Results Q2 FY20	Amortization Expense	Non-GAAP Results Q2 FY20
BSSG			
Revenue	124.9	_	124.9
Gross profit	48.6	0.7	49.4
Gross profit margin	38.9%		39.5%
Operating expenses	(32.7)		(32.7)
Operating profit	16.0	0.7	16.7
Operating profit margin	12.8%		13.4%
BLS			
Revenue	95.3	-	95.3
Gross profit	41.7	2.0	43.7
Gross profit margin	43.7%		45.8%
Operating expenses	(35.6)		(35.6)
Operating profit	6.1	2.0	8.1
Operating profit margin	6.4%		8.5%

Reconciliation of GAAP to Non-GAAP – Q1'20 Continuing Operations



	GAAP Results Q1 FY20	Merger and Acquisition Costs	Amortization Expense	Restructuring Charges	Tax Effect on Adjustments	Other Tax Items	Non-GAAP Results Q1 FY20
Revenue	210.5	_	_	_	_	_	210.5
Gross profit	85.0	_	2,7	_	_	_	87.7
Gross profit margin	40.4%		2.7				41.6%
Operating Expenses	(73.7)	0.2	7.9	_	-	-	(65.6)
Restructuring charges	(0.6)	-	-	0.6	-	-	-
Operating profit	10.7	0.2	10.6	0.6	-	-	22.0
Operating profit margin	5.1%						10.5%
Interest expense, net	(0.0)	_	-	-	-	-	(0.0)
Other income (expense), net	(0.4)	-	-	-	-	-	(0.4)
Income tax benefit (provision)	3.0	-	-	-	(2.7)	(5.2)	(4.9)
Net Income	13.2	0.2	10.6	0.6	(2.7)	(5.2)	16.6
Diluted EPS	0.18	0.00	0.14	0.01	(0.04)	(0.07)	0.23

GAAP to Non-GAAP Reconciliation Q1'20 Segments – Continuing Operations



	GAAP Results Q1 FY20	Amortization Expense	Non-GAAP Results Q1 FY20
BSSG			
Revenue	118.8	-	118.8
Gross profit	46.3	0.7	47.0
Gross profit margin	39.0%		39.6%
Operating expenses	(32.0)		(32.0)
Operating profit	14.3	0.7	15.0
Operating profit margin	12.0%		12.6%
BLS			
Revenue	91.7	-	91.7
Gross profit	38.7	1.9	40.6
Gross profit margin	42.2%		44.3%
Operating expenses	(34.7)		(34.7)
Operating profit	4.0	1.9	6.0
Operating profit margin	4.4%		6.5%

Reconciliation of GAAP to Non-GAAP – Q2'19 Continuing Operations



	GAAP Results Q2 FY19	Merger and Acquisition Costs	Amortization Expense	Restructuring Charges	Loss on debt extinguishment	Tax Effect on Adjustments	Other Tax Items	Non-GAAP Results Q2 FY19
Revenue	198.4	-	-	-	-	-	-	198.4
Gross profit Gross profit margin	80.5 <i>40.6%</i>	-	2.8	-	-	-	-	83.3 <i>42.0%</i>
Operating Expenses Restructuring charges	(66.5) (0.4)	0.0	6.6 -	- 0.4	- -	- -	-	(59.8) -
Operating profit	13.7	0.0	9.4	0.4	-	-	-	23.5
Operating profit margin	6.9%							11.8%
Interest income, net	(7.7)	-	-	-	-	-	-	(7.7)
Loss on debt extinguishment	(9.1)	-	-	-	9.1	-	-	-
Other income (expense), net	(0.8)	-	-	-	-	-	-	(0.8)
Income tax benefit (provision)	1.0	-	-	-	-	(4.6)	0.8	(2.8)
Net Income (Loss)	(2.8)	0.0	9.4	0.4	9.1	(4.6)	0.8	12.2
Diluted EPS	(0.04)	0.00	0.13	0.01	0.13	(0.06)	0.01	0.17

GAAP to Non-GAAP Reconciliation Q2'19 Segments – Continuing Operations

Brooks

	GAAP Results Q2 FY19	Amortization Expense	Non-GAAP Results Q2 FY19
BSSG			
Revenue	112.9	-	112.9
Gross profit	46.0	0.9	46.9
Gross profit margin	40.7%		41.6%
Operating expenses	(28.0)		(28.0)
Operating profit	18.0	0.9	18.9
Operating profit margin	15.9%		16.7%
BLS			
Revenue	85.5	-	85.5
Gross profit	34.5	1.9	36.4
Gross profit margin	40.4%		42.6%
Operating expenses	(31.4)		(31.4)
Operating profit	3.1	1.9	5.0
Operating profit margin	3.7%		5.9%

Net Income Reconciliation to Adjusted EBITDA Q2'20 – Continuing Operations



	Q2'19	Q1'20	Q2'20
Net income	3.4	13.1	9.1
Income (loss) from discontinued operations, net of tax	(6.2)	0.1	0.1
Net income (loss) from continuing operations	(2.8)	13.2	9.2
Adjustments:			
Interest income	(0.3)	(0.7)	(0.1)
Interest expense	8.0	0.7	0.7
Income tax provision (benefit)	(1.0)	(3.0)	3.4
Depreciation	5.1	5.9	6.2
Amortization of intangible assets	9.4	10.6	10.4
Loss on extinguishment of debt	9.1	-	-
EBITDA-from Continuing Operations	27.4	26.7	29.8
Non-GAAP adjustments:			
Stock-based compensation	5.1	4.4	4.2
Restructuring charges	0.4	0.6	0.6
Restructuring related charges	-	-	-
Merger and acquisition costs / Other	0.0	0.2	0.3
Adjusted EBITDA - from Continuing Operations	32.9	31.9	34.8